OUR MISSION
Making better treatment options a reality
B. More Inc., a 501 (c)(3) non-profit lifescience company, is relentlessly focused on the development and commercialization
of psychedelic medicines that offer the potential to dramatically improve lives of tens of millions of people struggling with alcoholism (alcohol use disorder/AUD)
and other substance abuse disorders.
of psychedelic medicines that offer the potential to dramatically improve lives of tens of millions of people struggling with alcoholism (alcohol use disorder/AUD)
and other substance abuse disorders.
OUR APPROACH
Transforming best-in-class research into cutting-edge medicine
In partnership with world-leading addiction researchers at the NYU School of Medicine, B. More is undertaking clinical research with synthetic psilocybin (SYNP-101) to establish its safety and efficacy in treating alcoholism and other substance use disorders.
WHO WE ARE